SCHEMBL6288100

SCHEMBL6288100

COc1ccccc1NC(=O)Nc1ncc(-c2ccccc2)s1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
CNR1 P21554 1/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
KDR P35968 2/20 0.56
DGAT1 O75907 1/20 0.55
GSTO1 P78417 1/20 0.53
KDM4E B2RXH2 1/20 0.53
MAPT P10636 2/20 0.53
LPAR1 Q92633 1/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
CDK5 Q00535 1/20 0.52
SCD O00767 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
ADORA2A P29274 1/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5698413 0.84 CNR1 (0.57) CNR1MEN1KMT2AKDRGSTO1
SCHEMBL6286038 0.83 SMN1; SMN2 (0.65) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6287958 0.82 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6282764 0.82 CNR1 (0.63) NPC1RAB9ACNR1MEN1KMT2A
SCHEMBL6330245 0.82 KDR (0.70) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6278417 0.81 CNR1 (0.69) SMN1; SMN2NPC1RAB9ACNR1MEN1
SCHEMBL6279216 0.81 CNR1 (0.62) NPC1RAB9ACNR1MEN1KMT2A
SCHEMBL6284850 0.81 CNR1 (0.72) SMN1; SMN2NPC1RAB9ACNR1MEN1
SCHEMBL6282352 0.80 CCNE1 (0.58) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6281775 0.79 CNR1 (0.82) SMN1; SMN2NPC1RAB9ACNR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
EP-1124811-A1 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.p.A. (IT) 2001-08-22 EP claimed
WO-2000026203-A1 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2000-05-11 WO claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 SMN1; SMN2 2448/4885NPC1 2685/4885RAB9A 2674/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 SMN1; SMN2 2448/4885NPC1 2685/4885RAB9A 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.